{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7"],"submitter":["Calzetta L"],"pubmed_abstract":["The investigation of ensifentrine, an inhaled dual phosphodiesterase (PDE)3 and PDE4 inhibitor, for chronic obstructive pulmonary disease (COPD) maintenance therapy presents a significant clinical interest. Despite promising results from recent Phase III trials, a comprehensive synthesis of its therapeutic efficacy in COPD is lacking. This protocol outlines the first registered systematic review and meta-analysis in PROSPERO to assess the impact of ensifentrine on trough forced expiratory volume in the 1st second (FEV<sub>1</sub>) and acute exacerbations of COPD. By conducting a rigorous literature search and employing solid methodologies, this endeavour aims to provide robust evidence on the real efficacy of ensifentrine. Anticipated outcomes include a significant improvement in trough FE"],"journal":["Current research in pharmacology and drug discovery"],"pagination":["100195"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11284681"],"repository":["biostudies-literature"],"pubmed_title":["The novel inhaled dual PDE3 and PDE4 inhibitor ensifentrine for the treatment of COPD: A systematic review and meta-analysis protocol on trough FEV<sub>1</sub> and exacerbation according to PRISMA statement."],"pmcid":["PMC11284681"],"pubmed_authors":["Cazzola M","Calzetta L","Rogliani P","Gholamalishahi S"],"additional_accession":[]},"is_claimable":false,"name":"The novel inhaled dual PDE3 and PDE4 inhibitor ensifentrine for the treatment of COPD: A systematic review and meta-analysis protocol on trough FEV<sub>1</sub> and exacerbation according to PRISMA statement.","description":"The investigation of ensifentrine, an inhaled dual phosphodiesterase (PDE)3 and PDE4 inhibitor, for chronic obstructive pulmonary disease (COPD) maintenance therapy presents a significant clinical interest. Despite promising results from recent Phase III trials, a comprehensive synthesis of its therapeutic efficacy in COPD is lacking. This protocol outlines the first registered systematic review and meta-analysis in PROSPERO to assess the impact of ensifentrine on trough forced expiratory volume in the 1st second (FEV<sub>1</sub>) and acute exacerbations of COPD. By conducting a rigorous literature search and employing solid methodologies, this endeavour aims to provide robust evidence on the real efficacy of ensifentrine. Anticipated outcomes include a significant improvement in trough FE","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-04-08T18:57:45.11Z","creation":"2026-04-08T11:14:52.724Z"},"accession":"S-EPMC11284681","cross_references":{"pubmed":["39077681"],"doi":["10.1016/j.crphar.2024.100195"]}}